KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Liabilities and Shareholders Equity (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Liabilities and Shareholders Equity data on record, last reported at $3.5 billion in Q4 2024.

  • For Q4 2024, Liabilities and Shareholders Equity rose 0.83% year-over-year to $3.5 billion; the TTM value through Sep 2025 reached $3.5 billion, down 66.47%, while the annual FY2024 figure was $3.5 billion, 0.83% up from the prior year.
  • Liabilities and Shareholders Equity reached $3.5 billion in Q4 2024 per AMRX's latest filing, up from $3.5 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $4.4 billion in Q1 2020 and bottomed at $3.5 billion in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $3.8 billion, with a median of $3.8 billion recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: rose 9.28% in 2020, then fell 9.81% in 2021.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $4.0 billion in 2020, then fell by 1.66% to $3.9 billion in 2021, then fell by 3.56% to $3.8 billion in 2022, then decreased by 8.6% to $3.5 billion in 2023, then rose by 0.83% to $3.5 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $3.5 billion in Q4 2024, $3.5 billion in Q3 2024, and $3.5 billion in Q2 2024.